PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma.

Krisztian HomicskoPanagiota ZygouraMaxim NorkinStephanie TissotNicholas ShakarishviliSanjay PopatAlessandra Curioni-FontecedroMary O'BrienAnthony PopeRiyaz ShahPatricia FisherJames F SpicerAmy RoyDavid GilliganSylvie RusakiewiczEkaterina FortisNesa MartiRoswitha KammlerStephen P FinnGeorges CoukosUrania DafniSolange PetersRolf A Stahel

Published in: Journal for immunotherapy of cancer (2023)

We analyzed a large cohort of patients within a phase III study and found that not only PD-1+CD8 T cells but also PD-1+CD68+ macrophages are predictive. This data provides evidence for the first time for the existence of PD-1+macrophages in mesothelioma and their clinical relevance for immune checkpoint blockade.

Keyphrases

phase iii
end stage renal disease
clinical trial
ejection fraction
open label
peritoneal dialysis
electronic health record
big data
phase ii
patient reported outcomes
placebo controlled
study protocol